Related references
Note: Only part of the references are listed.CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development
Kenji Hashimoto
CANCERS (2021)
Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity
Sun K. Ho et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer A Systematic Review and Meta-analysis
Jianchun Duan et al.
JAMA ONCOLOGY (2020)
FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models
Matthew A. Lakins et al.
CLINICAL CANCER RESEARCH (2020)
Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity
Helen Kotanides et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Strategies for improving the management of immune-related adverse events
Aung Naing et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39+ CD8 T cells from primary and metastatic sites of epithelial ovarian cancers
Galam Leem et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Tumor-Localized Costimulatory T-Cell Engagement by the 4-1BB/HER2 Bispecific Antibody-Anticalin Fusion PRS-343
Marlon J. Hinner et al.
CLINICAL CANCER RESEARCH (2019)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity
Xinyue Qi et al.
NATURE COMMUNICATIONS (2019)
Scrublet: Computational Identification of Cell Doublets in Single-Cell Transcriptomic Data
Samuel L. Wolock et al.
CELL SYSTEMS (2019)
Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit
Jie Wang et al.
MABS (2019)
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial
Yuankai Shi et al.
LANCET HAEMATOLOGY (2019)
High-affinity PD-1 molecules deliver improved interaction with PD-L1 and PD-L2
Yanyan Li et al.
CANCER SCIENCE (2018)
Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer
Neil H. Segal et al.
CLINICAL CANCER RESEARCH (2018)
Crystal structures of the human 4-1BB receptor bound to its ligand 4-1BBL reveal covalent receptor dimerization as a potential signaling amplifier
Aruna Bitra et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab
S. Michael Chin et al.
NATURE COMMUNICATIONS (2018)
Limited Cross-Linking of 4-1BB by 4-1BB Ligand and the Agonist Monoclonal Antibody Utomilumab
Yan Li et al.
CELL REPORTS (2018)
CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs
Juan M. Zapata et al.
FRONTIERS IN IMMUNOLOGY (2018)
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies
Cariad Chester et al.
BLOOD (2018)
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
Neil H. Segal et al.
CLINICAL CANCER RESEARCH (2017)
PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
Jan Willem Kleinovink et al.
ONCOIMMUNOLOGY (2017)
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer
Clemence Granier et al.
ESMO OPEN (2017)
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer
Jennifer H. Yearley et al.
CLINICAL CANCER RESEARCH (2017)
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
Justin F. Gainor et al.
CLINICAL CANCER RESEARCH (2016)
Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies
Arantza Azpilikueta et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Turning a Negative into a Positive: Conversion of a Homodimer into a Heterodimer Using Negative State Repertoires
James A. Davey et al.
STRUCTURE (2016)
Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells
Blanca Homet Moreno et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity
Fernando Souza-Fonseca-Guimaraes et al.
ONCOIMMUNOLOGY (2016)
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Alena Gros et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface
Steven M. Lewis et al.
NATURE BIOTECHNOLOGY (2014)
A novel T cell-based vaccine capable of stimulating long-term functional CTL memory against B16 melanoma via CD40L signaling
Yufeng Xie et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2013)
Dendritic Cell Inhibition Is Connected to Exhaustion of CD8+ T Cell Polyfunctionality during Chronic Hepatitis C Virus Infection
Ian Gael Rodrigue-Gervais et al.
JOURNAL OF IMMUNOLOGY (2010)
Immune regulation by 4-1BB and 4-1BBL: complexities and challenges
Chao Wang et al.
IMMUNOLOGICAL REVIEWS (2009)
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
David Yin-Wei Lin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
CD137 expression in tumor vessel walls - High correlation with malignant tumors
K Broll et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2001)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
Share Paper
